BPC-157 (5mg Vial)

01 · At a glance

Quickstart Highlights

BPC-157 (pentadecapeptide) is widely studied preclinically for cytoprotection, angiogenesis, and tissue repair mechanisms. Human dosing standards are not established; the schedules below reflect commonly referenced research practices, not medical advice. Typical research schedules: 200–300 mcg once daily (Standard) or 250 mcg twice daily (Advanced) Reconstitution: Standard: 3 mL (1.67 mg/mL); Advanced: 2 mL (2.5 mg/mL) Units on 100-unit insulin syringes: Standard: 200–300 mcg → 12–18 units; Advanced: 250 mcg → 10 units Cycle length: 4–8 weeks depending on research design Storage: Lyophilized at −20 to −80 °C; after reconstitution 2–8 °C; avoid freeze–thaw Compliance: Research use only. Not approved for human use; prohibited in sport by WADA.

02 · Dosing & reconstitution

Dosing & Reconstitution Guide

A practical calculator-ready setup based on the imported protocol reference. Use these values as a math starting point, then verify every entry against your own vial, diluent, and professional guidance.

Standard / Gradual Approach (3 mL = 1.67 mg/mL)

Reference dose shown on this page: 5 mg.

Advanced / Aggressive Approach

Reconstitution Steps

1. Confirm the vial amount, unit, and diluent amount before entering values in the calculator.
2. Add diluent slowly down the inner wall of the vial when reconstitution is appropriate for the compound.
3. Swirl or roll gently until dissolved; avoid shaking unless the product instructions specifically say otherwise.
4. Label the vial with the date and concentration, then store according to the protocol and product instructions.

03 · What you'll need

Supplies Needed

Keep this as a planning checklist. TNHL does not sell or verify supplies on this page, and no supplier quality claims are made here.

Protocol Overview

• Reconstitution: ≤3 mL per vial; record concentration on label
• Storage: Lyophilized at −20 to −80 °C; reconstituted at 2–8 °C; avoid freeze–thaw

Dosing Protocol

• Reference dose shown on this page: 5 mg.
• If values change, rerun the calculator and update the protocol so future logs match the active plan.

Storage Instructions

• Lyophilized at −20 to −80 °C; after reconstitution 2–8 °C; avoid freeze–thaw Compliance: Research use only. Not approved for human use; prohibited in sport by WADA.
• Storage: Lyophilized at −20 to −80 °C; reconstituted at 2–8 °C; avoid freeze–thaw
• Keep mixed and unmixed items clearly labeled so inventory and dose logs stay accurate.

04 · Good to know

Important Notes

• This BPC-157 page is for educational research organization only.
• Confirm route, dose, contraindications, monitoring, storage, and cycle decisions with qualified professional guidance.
• Use sterile technique, rotate sites when applicable, and log missed doses, reactions, and inventory changes.

05 · How it works

How This Works

BPC-157 (pentadecapeptide) is widely studied preclinically for cytoprotection, angiogenesis, and tissue repair mechanisms.

Human dosing standards are not established; the schedules below reflect commonly referenced research practices, not medical advice.

Typical research schedules: 200–300 mcg once daily (Standard) or 250 mcg twice daily (Advanced)

Reconstitution: Standard: 3 mL (1.67 mg/mL); Advanced: 2 mL (2.5 mg/mL) Units on 100-unit insulin syringes: Standard: 200–300 mcg → 12–18 units; Advanced: 250 mcg → 10 units Cycle length: 4–8 weeks depending on research design

Storage: Lyophilized at −20 to −80 °C; after reconstitution 2–8 °C; avoid freeze–thaw Compliance: Research use only.

The library page pairs that educational context with calculator-ready vial math, so users can understand the protocol structure and then track their own entered values in one place.

06 · Daily habits

Lifestyle Factors

• Keep meals, training, sleep, and recovery notes in the journal so trends are easier to review.
• Track body metrics only if they are relevant to the user's goal and approved data sources.
• Use consistent timing and logging habits so adherence data is meaningful.

07 · What to expect

Potential Benefits & Side Effects

• Preclinical studies have reported improved healing markers in GI and musculoskeletal models; robust human safety/efficacy data are limited.
• Observed considerations in research contexts may include: Injection-site irritation or erythema Unknown long-term systemic effects; dose–response in humans is not established Regulatory and anti-doping compliance requirements

08 · Technique

Injection Technique

09 · Evidence

References